March 19, 2024
Amsterdam, the Netherlands - Royal Philips (http://www.philips.com/newscenter)
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced
that it is one of the leading patent applicants at the European Patent Office
(EPO). Building on more than 130 years of innovation, Philips' extensive global
R&D programs and collaborations position the company at the forefront of health
technology innovation. In 2023, Philips improved the health and well-being of
1.9 billion people with its innovations.
With 607 MedTech patent applications in 2023, Philips is the second largest
applicant in EPO's Patent Index 2023 in the field of medical technology. In
total, Philips contributed 1,299 patent applications across various domains,
solidifying its standing among the top 10 patent filers overall.
Roy Jakobs, CEO of Royal Philips, said "At Philips, our purpose is to improve
people's health and well-being through meaningful innovation. As such, we see
huge opportunities to make a difference through innovation, design, and
sustainability. We are partnering with our healthcare customers to increase
productivity and deliver better care for more people, and we want to empower
more people to take care of their health through our personal health
propositions. Our portfolio of patient- and people-centric innovations in
hardware, software, AI and services, supports care in the hospital and in the
home, and we are the preferred strategic and innovation partner for many
customers across the globe."
Emphasizing the potential of informatics and AI both within hospital settings
and at home, Philips is increasingly focusing its innovation efforts on these
fields. Philips is one of the leaders in AI-related patent applications in
healthcare and deploys approximately half of its R&D workforce in software
development. For example, Philips unlocks insights at scale from combined
imaging and monitoring data pools to improve workflows, enhance caregiver and
patient experience, and elevate care delivery, which positions the company as a
global leader and trusted partner in software, data and AI.
Renowned as a global innovator in health technology, Philips invested
approximately EUR 1.7 billion in research and development in 2023 to help drive
better care for more people. With 9% of sales, this is well above the industry
average. The company's extensive intellectual property portfolio includes
53,000 patent rights, 31,500 trademarks, 135,000 design rights, and 3,300 domain
names.
For further information, please contact:
Ben Zwirs
Philips External Relations
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com (mailto:ben.zwirs@philips.com)
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and well-being through meaningful
innovation. Philips' patient- and people-centric innovation leverages advanced
technology and deep clinical and consumer insights to deliver personal health
solutions for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-
guided therapy, monitoring, and enterprise informatics, as well as in personal
health. Philips generated 2023 sales of EUR 18.2 billion and employs
approximately 69,700 employees with sales and services in more than 100
countries. News about Philips can be found at www.philips.com/newscenter
(http://www.philips.com/newscenter).
Â